Cartesian Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 66

Employees

  • Stock Symbol
  • RNAC

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $11.30
  • (As of Tuesday Closing)

Cartesian Therapeutics General Information

Description

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 704 Quince Orchard Road
  • Gaithersburg, MD 20878
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Healthcare Technology Systems
Stock Exchange
NAS
Corporate Office
  • 704 Quince Orchard Road
  • Gaithersburg, MD 20878
  • United States

Cartesian Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cartesian Therapeutics Stock Performance

As of 08-Jul-2025, Cartesian Therapeutics’s stock price is $11.30. Its current market cap is $293M with 26M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.30 $10.77 $8.46 - $26.50 $293M 26M 80K -$1.10

Cartesian Therapeutics Financials Summary

As of 31-Mar-2025, Cartesian Therapeutics has a trailing 12-month revenue of $34.9M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 142,830 250,634 42,511 64,635
Revenue 34,932 38,913 26,004 110,777
EBITDA (35,899) (83,323) (239,998) 39,088
Net Income (38,310) (77,424) (219,710) 35,379
Total Assets 409,130 435,023 305,050 165,886
Total Debt 14,066 13,984 10,955 37,925
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cartesian Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cartesian Therapeutics‘s full profile, request access.

Request a free trial

Cartesian Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Cartesian Therapeutics‘s full profile, request access.

Request a free trial

Cartesian Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance p
Biotechnology
Gaithersburg, MD
66 As of 2024

Woburn, MA
 

Shelton, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cartesian Therapeutics Competitors (10)

One of Cartesian Therapeutics’s 10 competitors is IM Therapeutics, a Venture Capital-Backed company based in Woburn, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
IM Therapeutics Venture Capital-Backed Woburn, MA
Intensity Therapeutics Formerly PE-Backed Shelton, CT
Vitruvian Biomedical Angel-Backed Addison, TX
Collaborative Medicinal Development Venture Capital-Backed Mill Valley, CA
Sirnaomics Formerly VC-backed Gaithersburg, MD
You’re viewing 5 of 10 competitors. Get the full list »

Cartesian Therapeutics Patents

Cartesian Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023321906-A1 Compositions and methods related to immunoglobulin proteases and fusions thereof Pending 11-Aug-2022
EP-4568750-A1 Compositions and methods related to immunoglobulin proteases and fusions thereof Pending 11-Aug-2022
US-20240148841-A1 Compositions and methods related to immunoglobulin proteases and fusions thereof Pending 11-Aug-2022
US-20230381277-A1 High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance Pending 08-Apr-2022
US-20230372535-A1 Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents Pending 25-Mar-2022 A61K47/6931
To view Cartesian Therapeutics’s complete patent history, request access »

Cartesian Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cartesian Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cartesian Therapeutics‘s full profile, request access.

Request a free trial

Cartesian Therapeutics Acquisitions (1)

Cartesian Therapeutics’s most recent deal was a Merger/Acquisition with Selecta Biosciences. The deal was made on 13-Nov-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Selecta Biosciences 13-Nov-2023 Merger/Acquisition Drug Discovery
To view Cartesian Therapeutics’s complete acquisitions history, request access »

Cartesian Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 30, 2024

36.37 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,697

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view Cartesian Therapeutics’s complete esg history, request access »

Cartesian Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Selecta Biosciences Watertown, MA 2008

Cartesian Therapeutics FAQs

  • When was Cartesian Therapeutics founded?

    Cartesian Therapeutics was founded in 2016.

  • Where is Cartesian Therapeutics headquartered?

    Cartesian Therapeutics is headquartered in Gaithersburg, MD.

  • What is the size of Cartesian Therapeutics?

    Cartesian Therapeutics has 66 total employees.

  • What industry is Cartesian Therapeutics in?

    Cartesian Therapeutics’s primary industry is Biotechnology.

  • Is Cartesian Therapeutics a private or public company?

    Cartesian Therapeutics is a Public company.

  • What is Cartesian Therapeutics’s stock symbol?

    The ticker symbol for Cartesian Therapeutics is RNAC.

  • What is the current stock price of Cartesian Therapeutics?

    As of 08-Jul-2025 the stock price of Cartesian Therapeutics is $11.30.

  • What is the current market cap of Cartesian Therapeutics?

    The current market capitalization of Cartesian Therapeutics is $293M.

  • What is Cartesian Therapeutics’s current revenue?

    The trailing twelve month revenue for Cartesian Therapeutics is $34.9M.

  • Who are Cartesian Therapeutics’s competitors?

    IM Therapeutics, Intensity Therapeutics, Vitruvian Biomedical, Collaborative Medicinal Development, and Sirnaomics are some of the 10 competitors of Cartesian Therapeutics.

  • What is Cartesian Therapeutics’s annual earnings per share (EPS)?

    Cartesian Therapeutics’s EPS for 12 months was -$1.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »